Effective February 14, 2022, Dr. Steve Hughes will step down from his position as Chief Medical Officer of Arcturus Therapeutics Holdings Inc. (the Company), and will continue to support the Company and its programs for the immediate future in the role of Strategic Clinical Advisor. Dr. Kelly Lindert, the Company's Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.41 USD | +1.84% | +7.81% | +31.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.34% | 1.12B | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.33% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- ARCT Stock
- News Arcturus Therapeutics Holdings Inc.
- Arcturus Therapeutics Holdings Inc. Announces Executive Changes, Effective from February 14, 2022